Kiniksa Pharmaceuticals International, plc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Kiniksa Pharmaceuticals International has 7 disclosed suppliers and 3 disclosed customers in SEC filings.
Kiniksa Pharmaceuticals International, plc
92.18
SentenceIn September 2016, the Company entered into an asset purchase agreement (the "Biogen Agreement") with Biogen MA Inc. ("Biogen") to acquire all of Biogen's right, title and interest in and to certain assets used in or relating to vixarelimab and other antibodies covered by certain patent rights, including patents and other intellectual property rights, clinical data, know-how, and clinical drug supply.
SentenceIn connection with our acquisition of Primatope, we acquired the rights to an exclusive license to certain intellectual property rights controlled by BIDMC to make, use, develop and commercialize abiprubart under the BIDMC license agreement (the "BIDMC Agreement").
KNSA 10-Kaccession 0001104659-26-019168
SentenceIn December 2024, we initiated a collaborative study agreement with The Mayo Clinic (together with Johns Hopkins University) to investigate the effects of ARCALYST in the treatment of cardiac sarcoidosis.
KNSA 10-Kaccession 0001104659-26-019168
SentenceIn December 2017, the Company entered into a license agreement (as amended from time to time, the "MedImmune Agreement") with MedImmune, Limited (subsequently acquired by AstraZeneca PLC) ("MedImmune"), pursuant to which MedImmune granted the Company an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab.
KNSA 10-Kaccession 0001104659-26-019168
SentenceWe have also contracted with Samsung to document the technology transfer and enable commercial manufacturing, if successful.
KNSA 10-Kaccession 0001104659-26-019168
SentenceIn December 2024, we initiated a collaborative study agreement with The Mayo Clinic (together with Johns Hopkins University) to investigate the effects of ARCALYST in the treatment of cardiac sarcoidosis.
KNSA 10-Kaccession 0001104659-26-019168
SentenceIn August 2022, we entered into the Genentech License Agreement, pursuant to which we granted Genentech exclusive worldwide rights to develop and commercialize the Genentech Licensed Products.
KNSA 10-Kaccession 0001104659-26-019168
SentenceIn August 2022, we entered into a license agreement (the "Genentech License Agreement") with Genentech, Inc. and F. Hoffmann-La Roche Ltd. (collectively, "Genentech"), pursuant to which we granted Genentech exclusive worldwide rights to develop, manufacture and commercialize vixarelimab and related antibodies (each, a "Genentech Licensed Product").
KNSA 10-Kaccession 0001104659-26-019168
SentenceUntil such time as Huadong is able to manufacture ARCALYST, either on its own or through a third party CDMO, we are its only source of drug supply.
KNSA 10-Kaccession 0001104659-26-019168
Linked news
Expected move
Inputsspot 92.24exp Jan 15ATM strike 90ATM straddle 20.75IV 62%